
September
28-30, 2023
*Pre-conference:
September 25 – 27, 2023
Venue:
KFC Hall & Rooms
Ryogoku, Tokyo
17th International Symposium on IgA Nephropathy
TOKYO 2023
IIgNN
Program
https://www.m-toyou.com/iigann2023/

17TH INTERNATIONAL SYMPOSIUM ON IGA NEPHROPATHY (IIGANN)

Chinook Therapeutics Presents:

IgA Nephropathy: Where We Are and Where We Are Going

PRESENTED BY:

Adrian Liew
MD, MBBS, MRCP, FAMS, FASN, FRCP, MCLINEPID

Senior Consultant Nephrologist
Director of the Kidney and Transplant Practice
Mount Elizabeth Novena Hospital Singapore

September 28, 2023
12:15 — 1:15 pm

KFC Hall
KFC Hall & Rooms

Hernan Trimarchi MD, PhD, FISN, FACP, FASN

Professor of Medicine
Chief of Nephrology Service and Kidney Transplant
Hospital Británico de Buenos Aires Argentina



SUPPORTED BY

CHINOOK™ THERAPEUTICS
A Novartis Company

The Industry Symposium is not a Continuing Education (CE) activity

Welcome Message

During the past three years, the global pandemic of the new coronavirus infection has greatly affected our daily life as well as our scientific activities. In fact, the 16th International IgAN Symposium scheduled for Prague in 2021 was unfortunately forced to meet virtually. However, this infection has finally calmed down, and the 17th International IgAN Symposium 2023 can be held locally for face to face discussions with all of you, and we are very excited to be able to hold it again in Tokyo after a 17-year absence.

Thanks to the continuous efforts and research results of the participating nephrologists and researchers from all over the world, the pathogenesis and pathophysiology of this disease are being elucidated. This has led to rapid progress in the development of a variety of promising drugs, and more than 15 international clinical trials are currently underway. This symposium will cover all topics related to IgA nephropathy, from pathogenesis to treatments, and in particular, we would like to share the update information on these ongoing clinical trials with you. In addition, for the first time, we have planned a "Patients Forum" to be attended by patients from all over the world, including Asia, North and South America, and Europe. We would like to have discussions about this disease together with you from the patients' point of view as well.

The symposium is designed to be fruitful not only for clinicians and researchers working on IgA nephropathy, but also for all the stakeholders who will participate in the symposium, thus we do hope that all of you will enjoy the three days of the symposium.

Yusuke Suzuki

Congress chair of the 17th International Symposium on IgA Nephropathy, Tokyo 2023
Professor of Department of Nephrology,
Juntendo University Faculty of Medicine, Tokyo Japan

Organizing Committee

Program Committee

Congress chair
Yusuke Suzuki

IgAn Network President
Renato C. Monteiro

Jonathan Barratt

Heather N. Reich

Hitoshi Suzuki

Hernán Trimarchi

Scientific Committee

Suceena Alexander	Takahito Moriyama	Hitoshi Suzuki
Sean J. Barbour	Eri Muso	Yusuke Suzuki
Jonathan Barratt	Koichi Nakanishi	Kazuo Takahashi
Chee Kay Cheung	Yasuyuki Nagasawa	Sydney Tang
Loreto Gesualdo	Ichiei Narita	Vladimír Tesař
Ali Gharavi	Jan Novak	Hernán Trimarchi
Motoshi Hattori	Evangeline Pillebout	Muh Geot Wong
Ritsuko Katafuchi	Heather N. Reich	Kunihiro Yamagata
Tetsuya Kawamura	Dana V. Rizk	Takashi Yokoo
Krzysztof Kiryluk	Ian SD Roberts	Hong Zhang
Jicheng Lv	Yuko Shima	
Renato C. Monteiro	Akira Shimizu	

Floor Map

1F



2F



3F



Exhibition Room/Cloak/
Break Room (KFC Hall Annex)
Sep. 28 - 30



Exhibition Layout

3F KFC Hall Annex

Exhibitors

① Chinook
② Novartis
③ STADA
④ Omeros
⑤ IBL-Japan
⑥ IgAN Foundation

Floor Map

10F



Registration desk

	Sep. 26 (Tue)	Sep. 28 (Thu)	Sep. 29 (Fri)	Sep. 30 (Sat)
Opening hours	17:00-18:30	8:00-17:00	7:00-17:00	7:00-15:00

MEMO

The 17th International Symposium on IgA Nephropathy (IIGANN 2023) Program at a glance

Pre-conference period: Tuesday, September 26

18:00-19:00 **Industry Symposium 0 *open for the all delegates** KYOWA KIRIN **Venue**：10A (10F)

Research program in IgAN : Towards personalized risk-based management of IgAN

Date：Tuesday, September 26, 2023

Chair : Yusuke Suzuki

Speaker：Sean Barbour

● Closed meetings for a exchange of information between key opinion leaders (KOLs) and industry companies are scheduled during the pre-conference period from September 25 to 27.

The 17th International Symposium on IgA Nephropathy (IIGANN 2023) Program at a glance

DAY1 ：September 28 (Thu)

	KFC Hall (3F)	KFC Hall 2nd (2F)	Poster Room 10A (10F)
7:00			
	8:00 Registration desk open		
8:00			
9:00	9:30～9:40 Opening remarks 9:40～10:00 **IgAN Network Presidential Lecture**		
10:00	10:00～10:45 **Patients Forum**		10:00～13:35 **Poster check-in and set-up**
11:00	11:00～12:00 **Oral session 1** Molecular Pathogenesis O-01～O-05		
12:00	12:15～13:15 **Industry symposium 1** Chinook Therapeutics, Inc. IgA Nephropathy : Where we are and where we are going	12:15～13:15 **Industry symposium 2** Novartis IgA nephropathy : Insights into pathogenesis and clinical challenges	
13:00			
	13:35～14:35 **Oral session 2** Genetics and Epigenetics O-06～O-10		13:35～16:50 **Poster viewing**
14:00			
	14:35～15:35 **Oral session 3** Biomarkers O-11～O-15		
15:00			
16:00	15:50～16:50 **Oral session 4** Microbiome and Immunology O-16～O-20		
17:00		17:00～18:00 **International IgA Network Research Group: collaboration in patient-focused research**	
18:00			
	18:30 **Welcome reception at Sky Banquet AZUL, 25F, Dai-ichi Hotel Ryogoku**		
19:00			
20:00			

on-demand available after the symposium　LIVE live streaming available on the day

The 17th International Symposium on IgA Nephropathy (IIGANN 2023) Program at a glance

DAY2：September 29 (Fri)

	KFC Hall (3F)	KFC Hall 2nd (2F)	Poster Room 10A (10F)
7:00	7:00 Registration desk open		
	7:30～8:30 **Industry symposium 3** STADA AG／Calliditas NA Enterprises Inc. Evolving landscape in IgAN-Treating IgAN in 2023 and Beyond	7:30～8:30 **Industry symposium 4** Mitsubishi Tanabe Pharma Corporation How should we treat anemia in CKD patients to maximize their well-being?	7:30～11:20
8:00	8:35～9:50 **Symposium Part 1** Recent advance in treatment／international clinical treatment		
9:00			**Poster viewing**
10:00	10:00～11:00 **Symposium Part 2** Recent advance in treatment／international clinical treatment		
11:00			11:20～12:35 **Poster presentation**
12:00			12:35～18:00
13:00	13:00～14:00 LIVE **Industry symposium 5** Otsuka America Pharmaceutical and Otsuka Pharmaceutical Co., Ltd. Japan Understanding the role of APRIL in the pathogenesis of IgAN	13:00～14:00 LIVE **Industry symposium 6** Travere Therapeutics Global Diversity and Controversies in IgA Nephropathy : A Conversation with Experts	
14:00	14:30～15:00 **President Lecture** Tetsuya Kawamura, Yusuke Suzuki		
15:00	15:05～15:45 **Honorary Lecture** "Life time on IgAN" East Asia & West		**Poster viewing**
16:00	16:00～16:40 **Show case of future talent** How to succeed in Nephrology		
17:00		17:00～18:00 **Industry symposium 7** AstraZeneca K.K. SGLT2 : Old yet New	
18:00			
19:00			
20:00			

on-demand available after the symposium　LIVE live streaming available on the day

The 17th International Symposium on IgA Nephropathy (IIGANN 2023) Program at a glance

DAY3：September 30 (Sat)

	KFC Hall (3F)	KFC Hall 2nd (2F)	Poster Room 10A (10F)
7:00	7:00 Registration desk open		
		7:30～8:30 LIVE **Industry symposium 8** Vera Therapeutics Targeting the Source of IgA Nephropathy	7:30～13:10
8:00	8:30～9:30 **Oral session 5** Pathology and Complement O-21～O-25		
9:00			
10:00	9:30～10:40 **Oral session 6** Clinical Trial 1 O-26～O-31		**Poster viewing**
11:00	10:55～11:55 **Oral session 7** Clinical Trial 2 O-32～O-35、LB-1～LB-2		
12:00	12:10～13:10 **Industry symposium 9** Nippon Boehringer Ingelheim Co., Ltd／Eli Lilly Japan K.K. Biological responses induced by SGLT2 inhibitors	12:10～13:10 **Industry symposium 10** Kyowa Kirin Co., Ltd. A new insight into the treatment of anemia in chronic kidney disease	
13:00	13:30～15:10 **CME Workshop jointly held with JSN／ISN／APSN** ~ International comparison, East vs West ~		13:10～14:00 **Poster removal**
14:00			
15:00	15:20～16:00 **Awards Ceremony, Ceremony of change of convenor, Closing remarks and Commemorative photo**		
16:00	16:00～17:00 **Farewell party** KFC Hall lobby		
17:00			
18:00			
19:00	Oral session and Poster presentation are only available onsite and will not available on-demand service nor live streaming.		
20:00			

Scientific program

Day 1 Thursday, September 28

9:30-9:40 **Opening remarks** **Venue**：KFC Hall (3F)

9:40-10:00 **IgAN Network President Lecture** **Venue**：KFC Hall (3F)
Speaker：Renato C. Monteiro [France]

10:00-10:45 **Patients Forum** **Venue**：KFC Hall (3F)
Moderators：Jonathan Barratt [UK], Ritsuko Katafuchi [Japan]
Speakers：5 patients from Japan, Germany, UK, US and Argentina

11:00-12:00 **Oral session1 Molecular Pathogenesis** **Venue**：KFC Hall (3F)
Chairs：Jan Novak [US], Kazuo Takahashi [Japan]
Short talk："Pathogenesis of IgA Nephropathy: Omics Data Inform Glycomedicine"
Jan Novak [US]

O-01 Characteristics of kidney resident plasma cells in IgA nephropathy
Yuko Makita [Canada]

O-02 APRIL is activated in children IgAN triggered by sCD89
Lison Lachize Neanne [Canada]

O-03 Novel IgA autoantibodies against mesangial cells, anti-βII spectrin IgA, is essential for development of IgA nephropathy
Yoshihito Nihei [Japan]

O-04 Galactose deficiency alters the structure of IgA1 and mediates IgA1 deposition in the mesangium of patients with IgA nephropathy
Meijun Si [China]

O-05 Structure-Function Studies of IgG Autoantibodies in IgA Nephropathy: Defining Elements Important for Binding to Galactose-deficient IgA1
Todd J. Green [US]

12:15-13:15 **Industry Symposium 1** CHINOOK THERAPEUTICS A Novartis Company **Venue**：KFC Hall (3F)
IgA Nephropathy: Where we are and where we are going
Chair：Adrian Liew
Speaker：Hernán Trimarchi

Symposium Overview：
- Title "IgA Nephropathy：Where we are and where we are going"
- Learning Objectives：

i. Uncover the complexity of IgAN diagnosis, management, and challenges from a clinician perspective.
ii. Review the pathogenesis of IgAN along with the role of the Endothelin and APRIL pathways in IgAN.

※The name written in Oral Session is presenting author.

12:15-13:15 **Industry Symposium 2** NOVARTIS | Reimagining Medicine **Venue**：KFC Hall 2nd (2F)
IgA nephropathy：Insights into pathogenesis and clinical challenges
Chair：Heather Reich
Pathogenesis of IgA nephropathy：Current understanding
Speaker：Sydney Tang
Heterogeneity in clinical presentation and progression of IgA nephropathy
Speaker：Dana Rizk
The challenges with IgA nephropathy in clinical practice: Insights from real-world data
Speaker：Hong Zhang

Symposium Overview
Please join us for an interesting and informative session, in which renowned global medical experts will provide insights on the underlying pathogenesis and pathophysiology of IgA nephropathy. They will present the findings from the real-world IgA nephropathy disease specific program, case studies and discuss the challenges in clinical practice due to heterogeneity in IgA nephropathy. The ensuing panel discussion will allow the experts to further share their views related to disease pathogenesis and perspectives on the real-world clinical practice patterns in IgA nephropathy.

13:35-14:35 **Oral session2 Genetics and Epigenetics** **Venue**：KFC Hall (3F)
Chairs：Daniel Gale [UK], Krzysztof Kiryluk [US]
Short talk："Genetics and epigenetics in IgA nephropathy"
Daniel Gale [UK]

O-06 Complement CFH genetics impacts renal survival in IgA nephropathy
Anna Duval [France]

O-07 Clinical application of polygenic risk score in IgA nephropathy
Xu-Jie Zhou [China]

O-08 Genome-wide association analysis of protein coding variants in IgA nephropathy
Ming Li [China]

O-09 Multi-omics analysis based on Single-cell Transcriptome Sequencing and Proteomic Spectra Reveal α1-antitrypsin Effected on IgA Nephropathy
Changwei Wu [China]

O-10 GWAS uncovers novel mechanisms and potential therapeutic targets for IgA vasculitis
Lili Liu [US]

14:35-15:35 **Oral session3　Biomarkers**　**Venue**：KFC Hall (3F)

Chairs：Hitoshi Suzuki [Japan], Evangeline Pillebout [France]

Short talk：" Potential biomarkers for risk stratification of IgA nephropathy"
Hitoshi Suzuki [Japan]

O-11 The amount of complement factor H-related protein-1 in serum IgA immune complexes as a novel biomarker for IgA nephropathy
Yukako Ohyama [Japan]

O-12 Interim biomarker analysis from a randomized, double-blind, placebo-controlled, Phase 2 trial of sibeprenlimab (VIS649) in participants with immunoglobulin A nephropathy
Tak Mao Chan [China]

O-13 Single-Cell Analyses of Blood Reveal Distinct Immune Cell Signatures of IgA nephropathy
Xu-Jie Zhou [China]

O-14 Development of novel monoclonal antibody, EASON2, for IgA nephropathy
Tzu-Yu Liu [Taiwan]

O-15 Analysis of the NefIgArd Part A study population confirms Nefecon suppresses circulating levels of BAFF, APRIL, and soluble BCMA in IgA nephropathy
Nadia Nawaz [UK]

15:50-16:50 **Oral session4　Microbiome and Immunology**　**Venue**：KFC Hall (3F)

Chairs：Renato C. Monteiro [France], Loreto Gesualdo [Italy]

Short talk：" Intestinal dysbiosis of mucin-degrading bacteria induces autoimmunity in IgA nephropathy"
Renato C. Monteiro [France]

O-16 CARD9 Risk Locus for IgA Nephropathy Regulates Mucosal IgA Production
Patrick_J Gleeson [Ireland]

O-17 Possible mediation of tonsils to IgA nephropathy caused by cnm-positive Streptococcus mutans, a major pathogen of dental caries
Taro Misaki [Japan]

O-18 Gut Microbiota in Immunoglobulin A Nephropathy
Shigeaki Nakazawa [Japan]

O-19 Plasmacytoid dendritic cells are involved in the production of galactose-deficient IgA1
Yusuke Fukao [Japan]

O-20 Systematic microbiome and metabolome dysbiosis are associated with IgA nephropathy
Fengtao Cai [China]

17:00-18:00 **International IgA Nephropathy Network Research Group: collaboration in patient-focused research**　**Venue**：KFC Hall 2nd (2F)

Summary：
The International IgA Nephropathy Network Research Group is a network of over 60 researchers worldwide studying IgA nephropathy. Through extensive collaboration, we have developed unique multi-centre international databases and platforms to further researcher development in IgA nephropathy and improve patient outcomes. This presentation will review the structure and expertise of the group, models of collaboration with the group, and the benefits of collaborating with the group at various stages of research development. The main objective of this presentation is for you to learn more about how to partner with the International IgA Nephropathy Network Research Group across a variety of research domains.

Day 2 Friday, September 29

7:30-8:30 **Industry Symposium 3**　**Venue**：KFC Hall (3F)

Evolving landscape in IgAN – Treating IgAN in 2023 and Beyond

Chair：Yusuke Suzuki

Redefining Standards for IgAN Treatment in a Rapidly Evolving Landscape
Speaker：Jonathan Barratt

IgAN Treatment: a clinical update
Speaker：Richard Lafayette

Symposium Overview：
IgA Nephropathy (IgAN) is the most common glomerulonephritis worldwide and a significant contributor to End-Stage Renal Disease (ESRD). At our upcoming event, we invited experts in the field of IgAN to delve into the rapidly evolving landscape. We will explore the latest advancements and progressive strategies that are redefining the management of this disease. With IgAN peaking during the second and third decades of life, it becomes imperative to approach this disease with the urgency it deserves—preserving every nephron and extending dialysis-free survival. Our panel of experts will provide an overview of recent data revealing that even patients who might be considered "low-risk" face a significant risk of kidney failure before reaching the age of 50. Additionally, they will discuss novel therapeutic approaches and shed light on ongoing developments driven by an improved understanding of IgAN's pathophysiology.

7:30-8:30 **Industry Symposium 4**　**Venue**：KFC Hall 2nd (2F)

How should we treat anemia in CKD patients to maximize their well-being?

Chair：Kunihiro Yamagata

Speaker：Takehiko Wada

Symposium Overview：
Anemia in chronic kidney disease (CKD) patients is known to be associated with a high burden of morbidity and adverse clinical outcomes. While the role of anemia in patient outcomes specific to IgA nephropathy, as the primary disease, has yet to be established, several studies have suggested its association with worse outcomes. On the other hand, there is currently no consensus on the optimal degree of anemia improvement or the appropriate treatment approach.
This presentation aims to share the current knowledge on the significance of anemia and to discuss optimal therapeutic approaches to maximize the well-being of CKD patients.

8:35-9:50 **Symposium part1**　**Venue**：KFC Hall (3F)

Recent advance in treatment / international clinical treatment

Moderators：Dana V.Rizk [US], Sydney Tang [Hong Kong]

Speakers：

1. **PSL (Low-dose Testing) & MMF, HCQ**
   Jicheng Lv [China]
2. **Sparsentan/Atrasentan/Zibotentan & SGLT2i**
   Muh Geot Wong [Australia]

3-1. Mucosal targeting therapy ;Gut
Jonathan Barratt [UK]

3-2. Mucosa targeting therapy: Upper respiratory mucosa
Takashi Yokoo [Japan]

10:00-11:00 **Symposium part2** **Venue**：KFC Hall (3F)

Recent advance in treatment / international clinical treatment

Moderators：Hernán Trimarchi [Argentina],
Heather N. Reich [Canada]

Speakers：

1. B cell targeting therapy
Yusuke Suzuki [Japan]

2. Role of complement and its inhibition in IgAN
Richard Lafayette [US]

Panel Discussion "How do we use all these new drugs, alone or in combination?"

Daniel Cattran [Canada]
Koichi Nakanishi [Japan]
Yuko Shima [Japan]
and all the speakers and moderators of Symposium 1 and 2.

11:20-12:35 **Poster presentation (regular submission)** **Venue**：10A (10F)

Pathogenesis 1：P-01 - P-09
Pathogenesis 2：P-10 - P-19
Microbiome + genetics: P-20 - P-29, LB-3
Biomarkers 1：P-30 - P-38
Biomarkers 2：P-39 - P-47
Diagnosis or prediction: P-48 - P-57
Pathology and complement: P-58 - P-67, LB-4
Clinical Trial 1：P-68 - P-77
Clinical Trial 2：P-78 - P-87
*9 sessions will take place at the same time

13:00-14:00 **Industry Symposium 5** Otsuka | Visterra **Venue**：KFC Hall (3F)

Understanding the role of APRIL in the pathogenesis of IgAN

Moderator：Yusuke Suzuki

Speaker：Dana Rizk,
Yoshihito Nihei

Objectives:
1. Review background on IgAN and the four-hit IgAN pathogenesis
2. Discuss B-cell biology and review APRIL physiologic roles
3. Review scientific evidence that supports the role of APRIL in IgAN pathogenesis

13:00-14:00 **Industry Symposium 6** TRAVERE THERAPEUTICS **Venue**：KFC Hall 2nd (2F)

Global Diversity and Controversies in IgA Nephropathy: A Conversation with Experts

Speakers：Jonathan Barratt
Heather Reich,
Hernán Trimarchi,
Suceena Alexander

Symposium Overview：
The landscape of IgA nephropathy has evolved rapidly in recent years, with exciting prospects for the treatment of patients. But how much of this disease do we truly understand? Pathogenesis is still debated – significant geographic diversity exists in the epidemiology and disease progression along with potential differences in treatment response. Fundamental questions and controversies remain, and developing a better understanding will guide effective treatment strategies. Please join us as we assemble a panel of international experts led by Prof. Jon Barratt. Together, we will delve deeper and dissect IgA nephropathy, from its pathogenesis to potential treatments in 2023 and beyond.

14:30-15:00 **President Lecture** **Venue**：KFC Hall (3F)

Chair：Tetsuya Kawamura [Japan]

Speaker：Yusuke Suzuki [Japan]

15:05-15:45 **Honorary Lecture "Life time on IgAN" East Asia & West** **Venue**：KFC Hall (3F)

Chairs：Hernán Trimarchi [Argentina], Ichiei Narita [Japan]

Speakers：

1. My Journey on the Path to Understanding IgA Nephropathy: From Bench to Bedside
Yasuhiko Tomino [Japan]

2. Lifetime in IgA Nephropathy
Bruce A. Julian [US]

16:00-16:40 **Show case of future talent "How to succeed in Nephrology"** **Venue**：KFC Hall (3F)

Chairs：Renato C. Monteiro [France], Eri Muso [Japan]

Speakers：

1. **Genome-wide association analyses define the genetic architecture of IgA Nephropathy and pathogenic signaling pathways**
   Francesca Zanoni [Italy]
2. **Exploration the process and mechanism of renal poly-IgA1 deposition and development of targeted therapy for IgAN by long-lasting Chimeric Fusion between *Clostridium ramosum* IgA Protease and IgG Fc**
   Xinfang Xie [China]
3. **From Bench to Bedside: Patient Driven Research in IgA Nephropathy**
   Haresh Selvaskandan [UK]
4. **Oral commensal bacteria-induced IgA autoantibodies against mesangial cells initiate IgA nephropathy**
   Yoshihito Nihei [Japan]

17:00-18:00 **Industry Symposium 7** **Venue**：KFC Hall 2nd (2F)

SGLT2：Old yet New

Chair：Ichiei Narita

Speaker：Eisei Sohara

Symposium Overview：

SGLT (Sodium Glucose co-transporter) is a transporter for glucose reabsorption in the renal proximal tubules. It has been considered to be important for energy retention in the body, and SGLT mutations were found to cause "Renal Glucosuria" . After a period of decades, SGLT2 inhibitors have recently gained attention for their therapeutic application in the treatment of CKD. In this seminar, I would like to give an overview of this old and new SGLT2 and its inhibitors from the viewpoints of genetics, physiology, and clinical nephrology.

Day 3 Saturday, September 30

7:30-8:30 **Industry Symposium 8** **Venue**：KFC Hall 2nd (2F)

Targeting the Source of IgA Nephropathy

The Potential Role of BLyS and APRIL in the Pathogenesis of IgA Nephropathy: Implications for Dual Inhibition

Speaker：Chee Kay Cheung

Emerging Therapies in IgA Nephropathy: Targeted Mechanisms and Clinical Implications

Speaker：Richard Lafayette

Symposium Overview：

IgAN is a serious and progressive autoimmune disease of the kidney, for which there remains a high unmet medical need.

The 4-hit mechanism establishes that abnormal accumulation of Gd-IgA1 is the instigating process in IgAN, leading to the expression of anti-Gd-IgA1 antibodies and eventually immune complex formation and deposition in the glomerulus. B-cell differentiation and survival are critical to the formation of Gd-IgA1, and these processes are in turn driven by the cytokines BLyS (B lymphocyte stimulator) and APRIL (a proliferation-inducing ligand). By inhibiting the function of BLyS and APRIL, the disease process is targeted early in its pathogenesis.

In this symposium, we will review the immune mechanisms at the source of IgAN and describe how therapies targeting BLyS and APRIL reduce proteinuria and may preserve eGFR. We will also familiarize the audience with the growing understanding of BLyS/APRIL biology in health and disease.

8:30-9:30 **Oral session 5 Pathology and Complement** **Venue**：KFC Hall (3F)

Chairs：Mark Haas [US], Akira Shimizu [Japan]

Short talk："Complement and its Colocalization with Immunoglobulins in the Pathogenesis of IgA Nephropathy"
Mark Haas [US]

O-21 Histologic and immunologic markers to predict renal recurrence in IgA vasculitis nephritis
Karma Abukasm [Canada]

O-22 Validation of the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy: evidence from the VALIGA cohort
Ian SD Roberts [UK]

O-23 Machine Learning in Predicting T score in the Oxford Classification System of IgA Nephropathy
Xu-Jie Zhou [China]

O-24 Digital spatial profiling reveals early evidence of complement activity associated endocapillary hypercellularity in glomerular endothelial cells in IgA Nephropathy
Haresh Selvaskandan [UK]

O-25 Circulating alternative pathway complement cleavage factor Bb is associated with vascular lesions and outcomes in IgA nephropathy
Nicolas Maillard [France]

9:30-10:40 **Oral session 6　Clinical Trial 1**　**Venue**：KFC Hall (3F)

Chairs：Suceena Alexander [India], Chee Kay Cheung [UK]

Short talk：Landscape of Clinical Trials in IgAN -What's beyond the Horizon?
Suceena Alexander [India]

O-26 IgA1-Protease mRNA-LNP treatment in a mouse model expressing human IgA1 as a pre-clinical assay for IgA nephropathy
Bruno C. Silva [France]

O-27 Therapeutic effect of Hydroxychloroquine in IgA Nephropathy course (QUIgAN study)
Nicolas Maillard [France]

O-28 Utilizing machine learning for detecting patients with IgA nephropathy from a computerized medical bill database
Ryoya Tsunoda [Japan]

O-29 Evaluation of the safety and efficacy of adipose-derived mesenchymal stem cells (ADR-001) treatment for refractory IgA nephropathy
Kazuhiro Furuhashi [Japan]

O-30 BEYOND: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Zigakibart (BION-1301) in Adults with IgA Nephropathy
Dana Rizk [US]

O-31 Interim Analysis of a Global Phase 2 Randomized Clinical Trial of Sibeprenlimab (VIS649), an APRIL-Neutralizing Monoclonal Antibody, in Immunoglobulin A Nephropathy
Jonathan Barratt [UK]

10:55-11:55 **Oral session 7　Clinical Trial 2**　**Venue**：KFC Hall (3F)

Chairs：Dana V. Rizk [US], Jonathan Barratt [UK]

O-32 Thirty-six-week Efficacy and Safety of Atacicept 150 mg in the Randomized, Double-Blind, Placebo-Controlled Ph2b ORIGIN Study in Patients with IgAN and Persistent Proteinuria
Richard Lafayette [US]

O-33 Nefecon treatment response in Asian and White patient populations with immunoglobulin A nephropathy: A 2-year analysis of the phase III NefIgArd trial
Jonathan Barratt [UK]

O-34 Hematuria reduction in patients with IgAN following Nefecon treatment: A secondary analysis of the full 2-year NefIgArd Phase III trial results
Richard Lafayette [US]

O-35 ASSIST Study Design: A Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Patients with IgA Nephropathy (IgAN) on SGLT2i
Jonathan Barratt [UK]

LB-1 Sparsentan Treatment of Incident Patients With IgA Nephropathy as First-line Therapy : Interim Findings From the SPARTAN Trial
Chee Kay Cheung [UK]

LB-2 Effect of corticosteroids on kidney and safety outcomes in IgA nephropathy across different levels of proteinuria and eGFR : A post hoc analysis of the TESTING study
Dana Kim [Australia]

12:10-13:10 **Industry Symposium 9**　Boehringer Ingelheim　Lilly　**Venue**：KFC Hall (3F)

Biological responses induced by SGLT2 inhibitors

Chair：Yoshitaka Isaka

Speaker：Akira Nishiyama

Symposium Overview：
SGLT2 inhibitors have been reported to reduce cardiovascular and renal risks in patients with Type 2 diabetes, in addition to their primary function of lowering blood glucose levels. We conducted a basic analysis of the pharmacological mechanisms of action of SGLT2 inhibitors and demonstrated that they induce transient diuresis accompanied by an increase in urinary glucose. SGLT2 inhibitors also have an influence on blood pressure, accompanied by a decrease in sympathetic nerve activity, and exert an influence on ischemia by reducing renal interstitial glucose concentration. Furthermore, a series of adaptive responses are triggered to compensate for the energy and water loss caused by SGLT2 inhibitors. These responses are similar to the "aestivation-like response" that we recently discovered and may exert an influence on organs.

12:10-13:10 **Industry Symposium 10**　KYOWA KIRIN　**Venue**：KFC Hall 2nd (2F)

A new insight into the treatment of anemia in chronic kidney disease

Chair：Takashi Yokoo

Speaker：Hiroshi Nishi

Symposium Overview：
The cause of anemia in chronic kidney disease is the relative inadequacy of supply to hematopoietic demand due to impaired production of erythropoietin associated with impaired renal function. The mainstays of anemia treatment are erythropoietin stimulating agents and adequate iron supplementation. In particular, the advent of hypoxia-inducible factor prolyl hydroxylase inhibitors in the past few years has revolutionized our understanding of the pathogenesis of anemia, pharmacological treatment strategy, and the physician-patient relationship. The current understanding and applications of those treatments will be outlined from both basic and clinical viewpoints.

13:30-15:10 **CME Workshop jointly held with JSN/ISN/APSN** **Venue**：KFC Hall (3F)

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

International comparison, East vs West

Moderators：Vladimír Tesař [Czech Republic], Muh Geot Wong [Australia]

Speakers：

1. **The epidemiology of IgA nephropathy**
   Sean J. Barbour [Canada]
2. **Genetics of IgA nephropathy**
   Krzysztof Kiryluk [US]
3. **The pathogenesis of IgAN: Where is pathogenic IgA produced?**
   Heather N. Reich [Canada]
4. **Pathology of IgA nephropathy: a global perspective**
   Ian SD Roberts [UK]
5. **Current Treatment and New Insights in IgA Nephropathy**
   Hong Zhang [China]

Panel discussion

Mark Haas [US]
Francesco Paolo Schena [Italy]
Takahito Moriyama [Japan]
Yasuyuki Nagasawa [Japan]
and all the speakers and moderators

15:20-16:00 **Awards ceremony, Ceremony of changing convenor, Closing remarks and commemorative photo session**

Poster presentation (Regular submission)

※ The name written in Poster presentation is presenting author.

Pathogenesis 1

Day 2 Friday, September 29 11:20-12:35 **Venue**：10A (10F)

Moderator：Hong Zhang [China]

P-01 Soluble Fc receptor I (CD89) as crucial inflammatory actor in childhood IgA nephropathy
Alexandra Cambier [Canada]

P-02 Nucleotide-sensing TLR9/TLR7: therapeutic candidate for IgA nephropathy
Mingfeng Lee [Japan]

P-03 Exploration of the molecular mechanism of hydroxychloroquine in the treatment of IgA nephropathy based on network pharmacology and molecular dynamics simulation
Yuyuan Liu [China]

P-04 LIF/LIFR/gp130/JAK2/STAT1 pathway drives overproduction of galactose-deficient IgA1 in IgA1-producing cell lines derived from tonsils of patients with IgA nephropathy
Koshi Yamada [Japan]

P-05 A human origin anti-GdIgA1 antibody and its implications in IgAN
Haipei Tang [China]

P-06 The mechanism for cell-surface expression of beta2-spectrin at mesangial region
Hiroyuki Iwasaki [Japan]

P-07 Interaction of isolated IgA1-containing circulating immune complexes with cultured primary human mesangial cells via integrin β1
Zhi qiang Huang [US]

P-08 Reverse Engineering of IgG to Enhance Binding to Galactose-deficient IgA1: An Effort to Define Interactions in IgA Nephropathy
Todd J. Green [US]

P-09 Cell-surface glycophenotyping of IgA1-secreting cells reveals glyco-memory and correlations with sialylation of Gd-IgA1
Colin R. Reily [US]

Pathogenesis 2

Moderator：Loreto Gesualdo [Italy]

P-10 Heterozygous mutations in factor H aggravate pathological damage in a stable IgA deposition model induced by LCWE
Yaping Dong [China]

P-11 Tackling IgA Nephropathy with systems medicine - a personal view
Julio Saez-Rodriguez [Germany]

P-12 Adaptive remodeling of mesangial matrix proteoglycan composition during IgA nephropathy
Kerstin Ebefors [Sweden]

P-13 Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan is protective in the gddY mouse model of IgA nephropathy to a greater extent than losartan
Hajime Nagasawa [Japan]

P-14 Characterization of pathogenic circulating immune complexes in patients with progressive versus non-progressive IgA nephropathy
Zhi Qiang-Huang [US]

P-15 Comprehensive molecular analysis of tonsillar tissues in IgA nephropathy
Mayuko Kawabe [Japan]

P-16 Galectin-3 plays a pathogenic role in the development of IgA nephropathy
Shuk-Man Ka [Taiwan]

P-17 Regulatory function of FcγRIIB involving the NLRP3 inflammasome in an experimental IgA nephropathy
Ann Chen [Taiwan]

P-18 Colocalization of IgG and IgA Heavy and Light Chains in Glomerular Deposits of IgA Nephropathy Using High-Resolution Confocal Microscopy: Correlation with MEST-C Scores
Dana V. Rizk [US]

P-19 mTOR inhibitors reduce IgA1 deposits and glomerular inflammation in a humanized mouse IgAN model
Alexandra Cambier [Canada]

Microbiome+genetics

Moderator：Krzysztof Kiryluk [US]

P-20 Relation between Porphyromonas gingivalis infection in oral cavity and elevated galactose-deficient IgA1 in IgA nephropathy
Seigo Ito [Japan]

P-21 Prevalence of periodontitis-related bacteria in tonsils of IgA nephropathy patients compared with those in habitual tonsilitis patients
Yasuyuki Nagasawa [Japan]

P-22 Mixed-linkage glucans in Shen Ping decoction, traditional Chinese medicine for IgA nephropathy, inhibit cellular proliferation and signaling induced by PDGF in human mesangial cells
Xianwen Zhang [China]

P-23 Characterizations of the gut virome in patients with IgA nephropathy
Xu-Jie Zhou [China]

P-24 RNA-Seq analysis of tonsils in patients with IgA nephropathy
Kazunori Satokata [Japan]

P-25 Genome-wide DNA methylation association study identify DNA methylation associated with end stage renal disease
Xiaohong Zhou [China]

P-26 Identification of susceptibility loci and relevant cell type for IgA nephropathy in Han Chinese by integrative genome-wide analysis
Ming Li [China]

P-27 Prevalence and trend of biopsy-proven IgA nephropathy in China: a systematic review
Changwei Wu [China]

LB-3 New genes potentially involved in IgA nephropathy from DNA methylation analysis
Fabio Sallustio[Italy]

P-28 Comparative proteomic analysis of laser microdissected glomeruli under in IgA nephropathy
Yudai Tsuji [Japan]

P-29 Identifying potential biomarkers for the diagnosis and treatment of IgA nephropathy based on transcriptome analysis
Ting Gan [China]

Biomarkers 1

Moderator：Evangeline Pillebout [France]

P-30 Longitudinal changes in IgA1 O- and N-glycoforms in IgA nephropathy
Masaya Hirayama [Japan]

P-31 Elevated serum Gd-IgA1/s.IgA levels and not serum Gd-IgA1 alone is an independent risk factor for composite outcome in South Asian IgAN
Suceena Alexander [India]

P-32 Relevance of serum APRIL as a biomarker in South-Asian prospective longitudinal observational IgA nephropathy cohort (GRACE-IgANI)
Suceena Alexander [India]

P-33 GalD: An available and high-performing lectin-based test for serum galactose-deficient IgA1
William J. Placzek [US]

P-34 Analysis of the NefIgArd Part A study population confirms Nefecon suppresses circulating levels of IgA-containing immune complexes in IgA nephropathy
Vicky Cotton [UK]

P-35 Analysis of the NefIgArd Part A study population confirms that Nefecon modulates circulating levels of the chemokines CXCL5, CCL11, and CCL13 in IgA nephropathy
Roisin Thomas [UK]

P-36 High Serum IgA/C3 Ratio Predict Progression of IgA Nephropathy: A Retrospective Study
Shiao-Yu Chen [Taiwan]

P-37 Clinical significance of glomerular and circulating apoptosis inhibitor of macrophage in IgAN nephropathy
Rina Kato [Japan]

P-38 The serial changes of clinical parameters after tonsillectomy and steroid pulse therapy in IgA nephropathy
Takahito Moriyama [Japan]

Biomarkers 2

Moderator：Sydney Tang [Hong Kong]

P-39 Basophils are activated by sera from IgA nephropathy patients
Senka Sendic [Sweden]

P-40 High Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Indicate Poor Renal Survival in Patients with IgA Nephropathy
Chia-Tien Hsu [Taiwan]

P-41 Prognostic Value of Cholesterol to High-Density Lipoprotein Cholesterol Ratio (Chol/HDL-C) in IgA Nephropathy Patients
Chia-Hang Yu [Taiwan]

P-42 Association of urinary C4d levels and CKD progression in a large IgA nephropathy cohort
Yaping Dong [China]

P-43 Impact of non-immune factors on renal prognosis in adult IgA Vasculitis with Nephritis：A Long-Term Retrospective Cohort Study
Yi Guan [China]

P-44 Impact of obesity on prognosis of IgA nephropathy separately analyzed by renal function and sex
Yuki Ariyasu [Japan]

P-45 DOES FEMALE GENDER AFFECT THE PROGNOSIS OF PATIENTS WITH IGAN AFTER KIDNEY TRANSPLANT?
Dita Maixnerova [Czech Republic]

P-46 Clinical renal outcomes of immunoglobulin A nephropathy associated with hepatitis B or hepatitis C virus infection
Mu Chi Chung [Taiwan]

P-47 Elevated inflammatory biomarkers are risk factors for composite outcome in South Asian IgAN
Suceena Alexander [India]

Diagnosis or prediction

Moderator：Kunihiro Yamagata [Japan]

P-48 IGA NEPHROPATHY: A 25-YEAR ARGENTINIAN SINGLE CENTER EXPERIENCE
Hernan Trimarchi [Argentina]

P-49 Proteinuria and disease progression in the RaDaR IgAN cohort
Bruce Hendry [US]

P-50 Diagnostic Prediction of IgA Nephropathy by Machine Learning Based on Blood and Urine Tests
Ryunosuke Noda [Japan]

P-51 Work, productivity, and activity impairment in patients with immunoglobulin A nephropathy: Results from a real-world study
Richard Lafayette [US]

P-52 Characteristics of patients with gross hematuria after COVID-19 mRNA vaccination: a prospective cohort study
Ryousuke Aoki [Japan]

P-53 IgA nephropathy: A real-world comparison between disease severity, symptom burden, and treatment satisfaction reported by patients and nephrologists
Richard Lafayette [US]

P-54 Clinical and pathological characteristics in elderly patients with IgA nephropathy
Yaping Dong [China]

P-55 Clinical Impact of SARS-CoV-2 infection on IgA Nephropathy
Masahiro Okabe [Japan]

P-56 Microscopic hematuria in IgA nephropathy predicts gross hematuria following COVID-19 vaccination
Shinya Yokote [Japan]

P-57 Diagnostic pathways in immunoglobulin A nephropathy in Japan: Results from a real-world survey
Mingfeng Lee [Japan]

Pathology and complement

Moderator：Jan Novak [US]

P-58 Protocol and Rationale for a Multi-center, Multi-arm and Multi-stage (MAMS) Randomized Embedded Adaptive Platform Clinical Trial in South Asian Kidney Biopsy-Proven IgA nephropathy
Selvin Sundar Raj Mani [India]

P-59 Mesangial Matrix Deposition Predict Worse Renal Outcomes in Chinese Patients with IgA Nephropathy
Jia Wei Hsu [Taiwan]

P-60 Higher colocalization of IgA and complement C3 in the glomerular immunodeposits of patients with IgA nephropathy is associated with worse histopathologic findings
Lea Novak [US]

P-61 RSV G activates the alternative pathway of complement and promotes HGECs to recruit CD16 + monocytes to participate in IgAN pathogene
Liying Luo [China]

P-62 CLINICAL AND PATHOLOGICAL SPECTRUM OF PATIENTS WITH IgA NEPHROPATHY: A SINGLE CENTRE STUDY
Arpit Jain [India]

P-63 Clinicopathological characteristics of the pediatric IgA nephropathy with eGFR
Yuko Shima [Japan]

P-64 Serologic and histologic predictors of long term renal outcome in biopsy-confirmed IgA nephropathy
Shang-Feng Tsai [Taiwan]

P-65 Progression of IgA Nephropathy is associated with mesangial C3 deposition but not disease-susceptible variant in CFH
XuJie Zhou [China]

LB-4 Glomerular spatial transcriptomics of IgA nephropathy according to the presence of mesangial proliferation and crescent formation
Park Sehoon [Korea]

P-66 OXFORD SCORE AND CLINICAL IMPLICATIONS IN PRIMARY IGA NEPHROPATHY. A SINGLE CENTER 25-YEAR EXPERIENCE IN ARGENTINA
Hernan Trimarchi [Argentina]

P-67 ARE ACTIVE CRESCENTS A RISK MARKER OF PROGRESSION IN PRIMARY IGA NEPHROPATHY? A SINGLE-CENTER 25-YEAR EXPERIENCE
Hernan Trimarchi [Argentina]

Clinical Trial 1

Moderator：Motoshi Hattori [Japan]

P-68 TheEffect of Podocyte Foot Process Effacement on Kidney Prognosis and Response to Immunosuppressive Therapy in IgA Nephropathy
Sufang Shi [China]

P-69 The utility of proteinuria and hematuria remission criteria by the Japanese Society of Nephrology in IgA-nephropathy patients
Yoshinari Yasuda [Japan]

P-70 The Effectiveness and Safety of Spironolactone in the Treatment of IgA Nephropathy: A Retrospective Cohort Study
Da Shang [China]

P-71 The association of 5-year therapeutic responsiveness with long-term renal outcome in IgA nephropathy
Hideo Tsushima [Japan]

P-72 IGA NEPHROPATHY SPONSORED CLINICAL TRIALS IN SOUTH AMERICA AND POTENTIALITY OF THE REGION FOR GLOBAL REPRESENTATION. A FIVE-YEAR EXPERIENCE
Hernan Trimarchi [Argentina]

P-73 Intensive Blood Pressure Control on the Progression of IgA Nephropathy: A Cohort Study using Marginal Structural Models
Chen Tang [China]

P-74 Clinical and mechanistic studies of two Chinese herbal formulations for treatment of IgA nephropathy
Lin Wang [China]

P-75 Associations of Corticosteroid Therapy and Tonsillectomy with Kidney Outcome in Patients with Advanced IgA nephropathy: A Nationwide Retrospective Cohort Study
Kyoko Watanabe [Japan]

P-76 Association of tonsillectomy in IgA nephropathy patients with JSN remission within 2 years of follow-up
Yoshinari Yasuda [Japan]

P-77 Association of hematuria relapse after the remission period with intensive treatment is associated with IgA nephropathy outcomes
Yoshinari Yasuda [Japan]

Clinical Trial 2

Moderator：Chee Kay Cheung [UK]

P-78 Current status of treatments for IgA nephropathy in Japan: Lessons from medical claim database
Keiichi Matsuzaki [Japan]

P-79 Multicenter retrospective study of Telitacicept in the treatment of IgA nephropathy
Yimeng Liu [China]

P-80 Durable proteinuria reduction over 2 years with Nefecon treatment: A secondary analysis of the full NefIgArd Phase III trial results
Richard Lafayette [US]

P-81 Long-term renal benefit over 2 years with Nefecon verified: The NefIgArd Phase III full trial results
Richard Lafayette [US]

P-82 Comparison of the dissolution profile of Nefecon and three other commercially available oral formulations of budesonide: implications for interchangeability
Jennifer Dressman [Germany]

P-83 Phase 1 Study in Healthy Adults of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Povetacicept (RUBY-1), a Dual BAFF/APRIL Antagonist for Treatment of Autoimmune Glomerulonephritis
Jiahua Li [US]

P-84 Updated Interim Results of a Phase 1/2 Study of Zigakibart (BION-1301) in Patients with IgA Nephropathy
Jonathan Barratt [UK]

P-85 Investigation of the efficacy of immunosuppressive therapy in IgA nephropathy using ΔeGFR calculated from long-term serial data
Atsunori Yoshino [Japan]

P-86 Challenges and lessons learnt from industry driven multi-centre global clinical trials in IgAN - A site investigators' perspective
Selvin Sundar Raj Mani [India]

P-87 COVID Vaccine Responses During Sibeprenlimab Treatment of IgA Nephropathy (IgAN): an Interim Analysis
Asher Schachter/ David Oldach [UK]

Acknowledgments

IIGANN2023 would like to thank to following sponsors, partners and supporters.

Endorsement

Gold Partners

Other Partners

MEMO

CHINOOK™ THERAPEUTICS
A Novartis Company

Changing the Course of Kidney Care™



Advancing a Diversified Pipeline of Potential Best-in-Class Programs

Program	Indication	Target Validation	Lead Optimization	IND-Enabling	Phase 1	Phase 2	Phase 3
Atrasentan (ALIGN)	IgA Nephropathy						*Phase 3 ongoing with topline data expected in Q4 2023*
Atrasentan (AFFINITY)	Basket of glomerular diseases					*Phase 2 ongoing*	
Atrasentan (ASSIST)	IgA Nephropathy					*Phase 2 enrolling*	
Zigakibart (BION-1301) (BEYOND)	IgA Nephropathy						*Phase 3 enrolling*
Zigakibart (BION-1301)	IgA Nephropathy					*Phase 1/2 ongoing*	
CHK-336	Primary & Idiopathic Hyperoxalurias				*Phase 1 HV study paused*		
Research & Discovery Programs	Rare, severe chronic kidney diseases			*Multiple programs*			

Atrasentan, zigakibart, and CHK-336 are investigational agents and have not been approved for any uses in patients.

Have you recently diagnosed a patient with IgA Nephropathy?

BEYOND™

The BEYOND study is a phase 3, randomized, double-blind, placebo-controlled study to evaluate an investigational medication called zigakibart* (BION-1301) in adults with primary immunoglobulin A nephropathy (IgAN) at risk of progressive loss of kidney function. Zigakibart is a novel, humanized monoclonal antibody that binds and blocks APRIL (A PRoliferation-Inducing Ligand). The goal of the BEYOND study is to evaluate the efficacy of zigakibart in reducing proteinuria and slowing down kidney disease progression. Approximately 272 patients will receive zigakibart or placebo by subcutaneous injection for 104 weeks. Virtual trial options may include telemedicine, home health nurse visits and the option to self-administer at home (subject to local regulations and sponsor approval). Patients may be reimbursed for trial-related expenses.

MAIN INCLUSION CRITERIA:

- Age 18 and older
- Biopsy-proven IgAN within the past 10 years (not due to secondary causes)
- eGFR of at least 30 mL/min/1.73m2 in (CKD-EPI)
- Total urine protein ≥ 1.0 g/day ***and*** UPCR ≥ 0.7 g/g at screening
- Receiving stable, maximally tolerated dose of angiotensin system inhibitor therapy (ACEi or ARB) for 12 weeks or more
- May be on a stable dose of SGLT2i, mineralocorticoid receptor antagonist (MRA), and/or endothelin receptor antagonist (ERA) ≥ 12 weeks prior to screening

Visit https://clinicaltrials.gov/ct2/show/NCT05852938 for more information; NCT05852938

* Zigakibart is an investigational drug that has not been approved by regulatory authorities. Efficacy and safety have not been established. There is no guarantee that it will become commercially available for the use(s) under investigation.

Novartis-sponsored symposium

IIgANN 2023

IgA nephropathy: Insights into pathogenesis and clinical challenges

Thursday, 28 September 2023 Lunch time Symposium | 12:15 pm –13:15 pm
KFC Hall 2, KFC Halls & Rooms, Tokyo, Japan

Welcome from the Chair

It is with immense pleasure that I welcome you to the Novartis-sponsored symposium at IIgANN 2023. Our expert faculty will discuss the disease pathogenesis of IgA nephropathy (IgAN) and the challenges in clinical practice due to heterogeneity in IgAN. Additionally, they will provide their perspectives on innovative approaches to improve the management of IgAN. The faculty will explore these topics through clinical case presentations, insights and learnings from real-world data, and an interactive panel discussion. During the symposium, your comments and questions will be highly appreciated by the faculty; we look forward to your active participation during the Q&A session. We hope you enjoy what will be an interesting and informative session!

Heather Reich
Baxter-Oreopoulos Division Director of Nephrology, Department of Medicine, University of Toronto, Canada

Agenda

12:15	**Welcome and introduction** Heather Reich
12:20	**Pathogenesis of IgA nephropathy: Current understanding** Sydney Tang
12:30	**Heterogeneity in clinical presentation and progression of IgA nephropathy** Dana Rizk
12:40	**The challenges with IgA nephropathy in clinical practice: Insights from real-world data** Hong Zhang
12:50	**Panel discussion with Q&A** All faculty (*Moderated by the chair*)
13:10	**Closing remarks** Heather Reich

Faculty

Heather Reich (Chair)
Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Heather Reich is the Oreopoulos-Baxter Division Director of Nephrology at the Department of Medicine of the University of Toronto and holds the Gabor Zellerman Chair in Nephrology Research. Her research is focused on identifying clinical and molecular markers of progressive glomerular diseases and identifying and evaluating novel therapies to improve the outcomes of patients with glomerulonephritis. She has contributed to the 2021 ISN-KDIGO guidelines for the treatment of glomerulonephritis.

Sydney Tang
Division of Nephrology, Department of Medicine, The University of Hong Kong, Hong Kong

Sydney Tang is the Chair of Renal Medicine and Yu Professor in Nephrology at The University of Hong Kong. His research interests include diabetic and proteinuric kidney disease and the treatment of IgA nephropathy. He is the President of the Asian Pacific Society of Nephrology, a member of the Executive Committee of KDIGO and the Chair of the CME Committee of the ISN.

Dana Rizk
Division of Nephrology, University of Alabama at Birmingham, Birmingham, Alabama, USA

Dana Rizk is a Professor of Medicine in the Division of Nephrology at the University of Alabama at Birmingham. Her clinical and research interests revolve around glomerular diseases and, in particular IgA nephropathy. She has served as the site Principal Investigator on many clinical trials and is part of several multi-disciplinary translational research projects focused on the role of biomarkers in IgA nephropathy.

Hong Zhang
Renal Division, Peking University First Hospital, Peking University Institute of Nephrology, Beijing, China

Hong Zhang is a Professor of Internal Medicine, and the Deputy Director of the Renal Division at Peking University First Hospital in China. Her major research is focused on the pathogenesis of and clinical therapeutic strategies in glomerulonephritis. She serves as a Board Committee Member of the Chinese Society of Nephrology, the Vice-president of the Nephrology Committee at the Beijing Society of Medicine, and a member of the ISN CME Advisory Committee, the ISN-ACT Committee and the ISN-CRP Committee.

Novartis Pharma AG

FUSE MLR ID: 297429 | Approval July 2023

NOVARTIS | Reimagining Medicine

Otsuka | Visterra
Otsuka Group of Companies

JOIN OUR SYMPOSIUM ON

UNDERSTANDING THE ROLE OF APRIL IN THE PATHOGENESIS OF IgAN

IIgANN '23 INDUSTRY-SPONSORED SYMPOSIUM

OBJECTIVES

1. Review background on IgAN and the four-hit IgAN pathogenesis
2. Discuss B-cell biology and review APRIL physiologic roles
3. Review scientific evidence that supports the role of APRIL in IgAN pathogenesis

SYMPOSIUM LOGISTICS

DATE AND TIME
Friday, September 29, 2023
13:00-14:00 JST

LOCATION
KFC Hall & Rooms
Room 1 KFC Hall

SYMPOSIUM CHAIR AND MODERATOR

YUSUKE SUZUKI, MD, PHD
Juntendo University Faculty of Medicine, Tokyo, Japan

PRESENTERS

DANA RIZK, MD
University of Alabama at Birmingham, Birmingham, Alabama, USA

YOSHIHITO NIHEI, MD, PHD
Juntendo University Faculty of Medicine, Tokyo, Japan

THE 17TH INTERNATIONAL SYMPOSIUM ON IgA NEPHROPATHY
September 28-30, 2023 | Tokyo, Japan

APRIL=a proliferation-inducing ligand. IgA=immunoglobin A. IgAN=IgA nephropathy.
This program is paid for by Otsuka Pharmaceutical Development & Commercialization, Inc.
Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.

July 2023 21US23EUP0015



In IgA Nephropathy

See how Endothelin-1 and Angiotensin II work in tandem to drive disease progression[1]

Learn more at **LowerProteinuria.com**

References: 1. Kohan DE, et al. *Kidney Int.* 2014;86:896-904

TRAVERE™ THERAPEUTICS

TRAVERE™ THERAPEUTICS

YOU'RE INVITED!

Global Diversity and Controversies in IgA Nephropathy: An Expert Conversation

Travere Therapeutics-Sponsored Symposium at the International Symposium on IgA Nephropathy, September 28–30, 2023

Symposium and panel discussion

KFC hall 2nd, KFC Hall & Rooms, Ryogoku, Tokyo

September 29, 2023
13:00–14:00 JST

Speakers:

Prof. Jonathan Barratt, *UK* **(Chair)**

Dr. Heather Reich, *Canada*

Dr. Hernán Trimarchi, *Argentina*

Dr. Suceena Alexander, *India*

The landscape of IgA nephropathy has evolved rapidly in recent years, with exciting prospects for the treatment of patients. **But how much of this disease do we truly understand?** Pathogenesis is still debated, and significant geographic diversity exists in the epidemiology and disease progression along with potential differences in treatment response. Fundamental questions and controversies remain, and developing a better understanding will guide effective treatment strategies. Please join us as we assemble a panel of international experts led by Prof. Jonathan Barratt.

Together, we will dive deeper and dissect IgA nephropathy, from its pathogenesis to treatments in 2023 and beyond.

MA-SP-23-0094

OMEROS

Improving the lives of patients—it's at the heart of everything we do

Omeros Corporation proudly sponsors the 17th International Symposium on IgA Nephropathy

Founded in 1994, Seattle-based Omeros is strategically building a deep and diverse pipeline of first-in-class molecules designed to improve and save the lives of patients.

We are tackling serious diseases and disorders to develop the most effective and safe therapeutics possible. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes.

At Omeros, we remain unrelenting in our efforts to benefit patients everywhere.

For more information, please visit Omeros.com.

vera therapeutics

Targeting the Upstream Source of IgA Nephropathy

origin 3

To learn about the **Phase 3** clinical trial of **atacicept** in **IgA nephropathy**, visit the**ORIGIN**iganstudy.com

Visit veratx.com for more information.



遺伝子組換えファブリー病治療剤

薬価基準収載

アガルシダーゼベータBS

点滴静注5mg「JCR」・点滴静注35mg「JCR」

アガルシダーゼ ベータ（遺伝子組換え）［アガルシダーゼ ベータ後続1］

生物由来製品　劇薬　処方箋医薬品*

*注意-医師等の処方箋により使用すること

※効能・効果、用法・用量、警告・禁忌を含む使用上の注意等の詳細については、電子化された添付文書をご参照ください。

製造販売元

JCRファーマ 株式会社

兵庫県芦屋市春日町3番19号

販売元（文献請求先及び問い合わせ先）

住友ファーマ株式会社

〒541-0045 大阪市中央区道修町 2-6-8

〈製品に関するお問い合わせ先〉

くすり情報センター

TEL 0120-034-389

受付時間／月～金 9:00～17:30（祝・祭日を除く）

https://sumitomo-pharma.jp/

2022年6月作成

IBL

Unique & Niche,
Antibody & ELISA

Gd-IgA1 KM55

ELISA

#27600 Gd-IgA1 Assay Kit - IBL

- Sample
  Serum, EDTA plasma, Urine
- Measurement Range
  1.56 - 100 ng/mL
- Sensitivity
  0.488 ng/mL
- Total Time
  about 2.5 hour

KM55

#10777 Anti-Human Gd-IgA1 (KM55) Rat IgG MoAb

- Application
  IHC
- Species
  Human
- Package size
  10µg, 100µg





Remarkable References

In Pursuit of Possibilities in IgA Nephropathy



VV-MEDMAT-90357 | Date of preparation: August 2023

EVOLVING LANDSCAPE IN IGAN

TREATING IGAN IN 2023 AND BEYOND

Friday, September 29th // 07:30–08:30 am, KFC hall

Program:

7:30–7:40 am	**Welcome** Professor Yusuke Suzuki
7:40–8:00 am	**Redefining Standards for IgAN Treatment in a Rapidly Evolving Landscape** Professor Jonathan Barratt
8:00–8:20 am	**IgAN Treatment: a clinical update** Professor Richard Lafayette
8:20–8:30 am	**Discussion** All

calliditas THERAPEUTICS

STADA

astellas

HIF-PH inhibitor, Drug for Treatment of Renal Anemia (Roxadustat Tablet)

Listed in the NHI drug price list

Evrenzo® Tablets 20mg 50mg 100mg

Powerful drug, Prescription-only drug
(Caution: Use only pursuant to the prescription of a physician, etc.)

■ Please refer to Electronic package inserts for “Indications”, “Dosage and Administration”, and “Precautions” .

Marketing Authorization Holder
Astellas Pharma Inc.
5-1, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo, Japan
Reference Request and Contact Information/
Medical Information, Astellas Pharma Inc.
Toll-free 0120-189-371
For Drug Information/ https://amn.astellas.jp/

Marketing Alliance
FibroGen Inc.